Assessment of orciprenaline and isoproterenol infusions in asthmatic patients.
D000293:Adolescent; D000328:Adult; D000403:Airway Resistance / Q000187:drug effects; D001249:Asthma / Q000188:drug therapy*; D001794:Blood Pressure / Q000187:drug effects; D002245:Carbon Dioxide / Q000097:blood; D004305:Dose-Response Relationship, Drug; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007275:Injections, Intravenous; D007545:Isoproterenol / Q000008:administration & dosage* / Q000627:therapeutic use; D008297:Male; D009921:Metaproterenol / Q000008:administration & dosage* / Q000627:therapeutic use; D008875:Middle Aged; D009130:Muscle, Smooth / Q000187:drug effects; D010100:Oxygen / Q000097:blood; D011650:Pulmonary Alveoli / Q000187:drug effects; D012119:Respiration / Q000187:drug effects*; D014797:Vital Capacity / Q000187:drug effects
D002245:Carbon Dioxide; D009921:Metaproterenol; D007545:Isoproterenol; D010100:Oxygen